{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:19:53Z","timestamp":1787026793904,"version":"build-2736575974"},"reference-count":255,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Early and accurate diagnosis of Parkinson's disease (PD) remains a challenge, hindering the efficient recruitment of patients into clinical trials aimed at disease modification. This underscores the urgent need for validated and clinically applicable biomarkers. Research continues to expand our knowledge of fluid biomarkers for detecting and monitoring PD progression. Cerebrospinal fluid \u03b1-synuclein (\u03b1-syn) seed amplification assays (SAA) have emerged as highly sensitive and specific biomarkers for the diagnosis of PD. The development of less invasive procedures using biological fluids such as serum or saliva would be more practical for routine clinical use. Recent data demonstrate the presence of pathogenic \u03b1-synuclein in the serum of PD patients compared with healthy controls, detected using real-time quaking-induced conversion (RT-QuIC) assays. Elevated ratios of pS129-\u03b1-syn and\/or oligomeric \u03b1-syn to total \u03b1-syn have also been reported in PD. Future research should clarify differences in protein aggregate formation across various synucleinopathies. Promising advances toward a clinically useful blood-based diagnostic test for PD include the quantification of proteins released from neural-derived extracellular vesicles (NDEVs), such as oligomeric and phosphorylated \u03b1-syn, tau, and disease-associated microRNAs. Given the role of neuroinflammation in PD pathogenesis, inflammatory biomarkers, including interleukin (IL)-6, IL-10, tumor necrosis factor-\u03b1(TNF-\u03b1), glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (YKL-40), and monocyte chemoattractant protein-1 (MCP-1), are under active investigation. Furthermore, fluid biomarkers associated with Alzheimer's disease pathology are being explored for their potential to predict motor and cognitive decline in PD and related synucleinopathies. Salivary EVs hold promise as a non-invasive source of PD biomarkers; however, robust validation in large, well-characterized cohorts is essential to improve the diagnostic and prognostic accuracy of PD.<\/jats:p>","DOI":"10.3389\/fnagi.2026.1835751","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:33:15Z","timestamp":1783920795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging biomarkers for Parkinson's disease in biological fluids"],"prefix":"10.3389","volume":"18","author":[{"given":"Petra","family":"Bago Ro\u017eankovi\u0107","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital Dubrava, Avenija Gojka \u0160u\u0161ka","place":["Zagreb, Croatia"]},{"name":"School of Medicine, Catholic University of Croatia","place":["Ilica, Zagreb, Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"\u0160imi\u0107","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine","place":["\u0160alata, Zagreb, Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fnagi.2021.638718","article-title":"Preanalytical stability of CSF total and oligomeric alpha-synuclein","volume":"3","author":"Abdi","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"105185","DOI":"10.1016\/j.nbd.2020.105185","article-title":"Oligomeric \u03b1-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease","volume":"148","author":"Agliardi","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4103\/1947-2714.147980","article-title":"Saliva \u03b1-synuclein and a high extinction coefficient protein: a novel approach in assessment biomarkers of Parkinson's disease","volume":"6","author":"Al-Nimer","year":"2014","journal-title":"N. Am. J. Med. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.0000000000000425","article-title":"CSF Abeta42 predicts early-onset dementia in Parkinson disease","volume":"82","author":"Alves","year":"2014","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000494435","article-title":"CXCL12 and CXCR4 in the peripheral blood of patients with Parkinson's disease","volume":"25","author":"Bagheri","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/mds.29257","article-title":"Blood markers of inflammation, neurodegeneration, and cardiovascular risk in early Parkinson's disease","volume":"38","author":"Bartl","year":"2023","journal-title":"Mov. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","article-title":"Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease","volume":"8","author":"Batzu","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","article-title":"alpha-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward","volume":"99","author":"Bellomo","year":"2022","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0147319","DOI":"10.1371\/journal.pone.0147319","article-title":"An Alzheimer's disease-derived biomarker signature identifies Parkinson's disease patients with dementia","volume":"11","author":"Berlyand","year":"2016","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/mds.29923","article-title":"\u03b1-synuclein seed amplification assays from blood-based extracellular vesicles in Parkinson's disease: an evaluation of the evidence","volume":"39","author":"Bernhardt","year":"2024","journal-title":"Mov. Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual frame work","volume":"69","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mds.26656","article-title":"Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-from pathophysiology to clinical practice","volume":"31","author":"Blennow","year":"2016","journal-title":"Mov. Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/brain\/awac258","article-title":"Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease","volume":"146","author":"Blommer","year":"2023","journal-title":"Brain"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23430","DOI":"10.3402\/jev.v3.23430","article-title":"Single-step isolation of extracellular vesicles by size-exclusion chromatography","volume":"3","author":"Boing","year":"2014","journal-title":"J. Extracell. Vesicles"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-019-02062-4","article-title":"Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review","author":"Bougea","year":"2019","journal-title":"J. Neural Transm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-021-01276-6","article-title":"Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies","volume":"9","author":"Brockmann","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e692","DOI":"10.1002\/ctm2.692","article-title":"Multi-omic landscape scoping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease","volume":"12","author":"Caldi Gomes","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11357-020-00192-2","article-title":"A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: anEXosomesinPArkiNson disease(EXPAND)ancillary study","volume":"42","author":"Calvani","year":"2020","journal-title":"Geroscience"},{"key":"B21","doi-asserted-by":"publisher","first-page":"41708653","DOI":"10.1101\/2025.01.16.633314","article-title":"Detection of alpha-synuclein seeding activity in tear fluid in patients with Parkinson's disease","volume":"12","author":"Canaslan","year":"2026","journal-title":"NPJ Parkinsons Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neulet.2018.12.030","article-title":"Alpha-synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease","volume":"696","author":"Cao","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3389\/fneur.2020.01043","article-title":"Differential diagnosis of multiple system atrophy-parkinsonism and Parkinson's disease using alpha synuclein and external anal sphincter electromyography","volume":"11","author":"Cao","year":"2020","journal-title":"Front Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3389\/fnins.2019.00889","article-title":"Phospho-S129 alpha-synuclein is present in human plasma but not in cerebrospinal fluid as determined by an ultrasensitive immunoassay","volume":"13","author":"Cariulo","year":"2019","journal-title":"Front. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","article-title":"In vivo distribution of alpha-synuclein in multiple tissues and biofluids in Parkinson disease","volume":"95","author":"Chahine","year":"2020","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17562864221150329","DOI":"10.1177\/17562864221150329","article-title":"Plasma extracellular vesicle tau, beta-amyloid, and alpha-synuclein and the progression of Parkinson's disease: a follow-up study","volume":"16","author":"Chan","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fneur.2019.01388","article-title":"Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients With Parkinson's Disease","volume":"10","author":"Chang","year":"2020","journal-title":"Front. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"577089","DOI":"10.1016\/j.jneuroim.2019.577089","article-title":"Inflammasome and alpha-synuclein in Parkinson's disease: a cross-sectional study","volume":"338","author":"Chatterjee","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41531-024-00664-8","article-title":"Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson's disease","volume":"10","author":"Che","year":"2024","journal-title":"NPJ Parkinsons Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3389\/fimmu.2018.02122","article-title":"Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer's disease, parkinson's disease, and amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.1c00010","article-title":"Synergistic association between plasma Abeta(1\u201342) and p-tau in Alzheimer's disease but not in Parkinson's disease or frontotemporal dementia","author":"Chiu","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"B32","doi-asserted-by":"publisher","author":"Chung","year":"2021","DOI":"10.1096\/fj.202100787R"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2408949121","DOI":"10.1073\/pnas.2408949121","article-title":"Measurement of alpha-synuclein as protein cargo in plasma extracellular vesicles","volume":"121","author":"Church","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic interactions between abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","article-title":"Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study","volume":"19","author":"Compta","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat. Protoc."},{"key":"B38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/brainsci11010119","article-title":"Cerebrospinal fluid alpha-synuclein species in cognitive and movements disorders","volume":"11","author":"Constatidines","year":"2021","journal-title":"Brain Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.25392","article-title":"Cognitive and pathological influences of tau pathology in Lewy body disorders","volume":"85","author":"Coughlin","year":"2019","journal-title":"Ann. Neurol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s13311-023-01379-z","article-title":"Fluid and biopsy based biomarkers in Parkinson's disease","volume":"20","author":"Coughlin","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/mds.27935","article-title":"Salivary microR-153 and microR-223 levels as potential diagnostic biomarkers of idiopathic Parkinson's disease","volume":"35","author":"Cressatti","year":"2020","journal-title":"Mov. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnmol.2018.00053","article-title":"\u03b1-synuclein heterocomplexes with \u03b2-amyloid are increased in red blood cells of Parkinson's disease patients and correlate with disease severity","volume":"11","author":"Daniele","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-020-01027-6","article-title":"Role of microgliosis and NLRP3 inflammasome in Parkinson's disease pathogenesis and therapy","author":"de Araujo","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26550","article-title":"A combined panel of salivary biomarkers in de novo Parkinson's disease","author":"De Bartolo","year":"2023","journal-title":"Ann. Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.parkreldis.2015.09.048","article-title":"Biomarkers in Parkinson's disease: advances and strategies","volume":"22","author":"Delenclos","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/mds.27001","article-title":"Tau\/alpha-synuclein ratio and inflammatory proteins in Parkinson's disease: an exploratory study","volume":"32","author":"Delgado-Alvarado","year":"2017","journal-title":"Mov. Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/mds.26662","article-title":"Biomarkers for dementia and mild cognitive impairment in Parkinson's disease","volume":"31","author":"Delgado-Alvarado","year":"2016","journal-title":"Mov. Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/brain\/awr015","article-title":"Salivary alpha-synuclein and DJ-1: Potential biomarkers for Parkinson's disease","volume":"134","author":"Devic","year":"2011","journal-title":"Brain"},{"key":"B49","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10571-019-00700-9","article-title":"Proteomics in human Parkinson's disease: present scenario and future directions","volume":"39","author":"Dixit","year":"2019","journal-title":"Cell. Mol. Neurobiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mds.22928","article-title":"Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment","volume":"25","author":"Duran","year":"2010","journal-title":"Mov. Disord."},{"key":"B51","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00401-021-02324-0","article-title":"Alpha-synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy","volume":"142","author":"Dutta","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-017-0935-1","article-title":"Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease","volume":"14","author":"Eidson","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson's disease: a systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov Disord"},{"key":"B55","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12974-019-1670-6","article-title":"Systemic activation of NLRP3 inflammasome and plasma alpha-synuclein levels are correlated with motor severity and progression in Parkinson's disease","volume":"17","author":"Fan","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"B57","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","article-title":"New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes","volume":"72","author":"Fereshtehnejad","year":"2015","journal-title":"JAMA Neurol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ene.14032","article-title":"The value of cerebrospinal fluid \u03b1-synuclein and the tau\/\u03b1-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology","volume":"27","author":"F\u00f8rland","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.nbd.2011.08.003","article-title":"Post mortem cerebrospinal fluid \u03b1-synuclein levels are raised in multiple system atrophy and distinguish this from the other \u03b1-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies","volume":"45","author":"Foulds","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/mds.26686","article-title":"Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease: P-LRRK2 predicts severity of PD","volume":"31","author":"Fraser","year":"2016","journal-title":"Mov. Disord."},{"key":"B62","doi-asserted-by":"publisher","first-page":"13647","DOI":"10.1021\/acs.analchem.0c03092","article-title":"Facile impedimetric analysis of neuronal exosome markers in Parkinson's disease diagnostics","volume":"92","author":"Fu","year":"2020","journal-title":"Anal. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"702639","DOI":"10.3389\/fnagi.2021.702639","article-title":"Alpha-synuclein as a biomarker of Parkinson's disease: good, but not good enough","volume":"13","author":"Ganguly","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/acn3.772","article-title":"\u03b1-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease","volume":"6","author":"Garrido","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/molecules27010088","article-title":"Implementing complementary approach to shape the mechanism of \u03b1-synuclein oligomerization as a model of amyloid aggregation","volume":"27","author":"Giampa","year":"2021","journal-title":"Molecular"},{"key":"B66","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/mds.27232","article-title":"Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson's disease features","volume":"33","author":"Goldman","year":"2018","journal-title":"Mov. Disord"},{"key":"B67","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"\u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid\u2014a systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov. Disord Clin. Pract."},{"key":"B68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"16272","DOI":"10.1038\/s41598-023-43096-9","article-title":"MicroRNAs in Parkinson's disease: a systematic review and diagnostic accuracy meta-analysis","volume":"13","author":"Gu\u00e9vremont","year":"2023","journal-title":"Sci. Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/01616412.2015.1133026","article-title":"Levels of IL-8 and TNF-alpha decrease in Parkinson's disease","volume":"38","author":"Gupta","year":"2016","journal-title":"Neurol. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e70508","DOI":"10.1111\/ene.70508","article-title":"Clinical validation of \u03b1-synuclein in salivary extracellular vesicles as a biomarker for Parkinson's disease: a longitudinal study","volume":"33","author":"Gurgone","year":"2026","journal-title":"Eur. J. Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.3390\/ijms27052470","article-title":"Connecting the dots: milestones in the history of extracellular vesicle research","volume":"27","author":"Guzowska","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"13276","DOI":"10.1038\/s41598-018-31517-z","article-title":"Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders","volume":"8","author":"Hall","year":"2018","journal-title":"Sci. Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease","volume":"31","author":"Hall","year":"2026","journal-title":"Mov. Disord."},{"key":"B75","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-008-0344-8","article-title":"The progression of pathology in longitudinally followed patients with Parkinson's disease","volume":"115","author":"Halliday","year":"2008","journal-title":"Acta Neuropathol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2217\/bmm-2019-0167","article-title":"Oligomeric alpha-synuclein is increased in basal tears of Parkinson's patients","volume":"13","author":"Hamm-Alvarez","year":"2019","journal-title":"Biomark. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimers. Res. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorders","volume":"16","author":"Hansson","year":"2017","journal-title":"Lancet Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.neuro.2017.04.007","article-title":"Environmental neurotoxicant manganese regulates exosome-mediated extracellular miRNAs in a cell culture model of Parkinson's disease","volume":"64","author":"Harischandra","year":"2018","journal-title":"Neurotoxicology"},{"key":"B81","author":"Hatano","year":"2024"},{"key":"B82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40478-019-0836-x","article-title":"Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B83","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fneur.2015.00091","article-title":"CSF neurofilament light chain is a biomarker of MSA and PSP, but not PD and DLB","volume":"6","author":"Herbert","year":"2015","journal-title":"Front. Neurol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"588","DOI":"10.20517\/evcna.2023.44","article-title":"Emerging evidence for dysregulated proteome cargoes of tau-propagating extracellular vesicles driven by familial mutations of tau and presenilin","volume":"4","author":"Hook","year":"2023","journal-title":"Extracell. Vesicles Circ. Nucl. Acids"},{"key":"B85","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional multiple pathology scores are associated with cognitive decline in lewy body dementias","volume":"25","author":"Howlett","year":"2015","journal-title":"Brain Pathol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fimmu.2019.00480","article-title":"CSF cytokines in aging, multiple sclerosis, and dementia","volume":"10","author":"Hu","year":"2019","journal-title":"Front. Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s10072-017-3088-1","article-title":"Changes of cerebrospinal fluid A\u03b242, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis","volume":"38","author":"Hu","year":"2017","journal-title":"Neurol. Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1212\/WNL.0000000000001308","article-title":"Parkinson disease with REM sleep behavior disorder: features, alpha-synuclein, and inflammation","volume":"84","author":"Hu","year":"2015","journal-title":"Neurology"},{"key":"B89","first-page":"S56","article-title":"Antemortem CSF tau and a beta biomarkers are predictive of postmortem alzheimer's disease pathology in autopsy confirmed lewy body disease","volume":"81","author":"Irwin","year":"2017","journal-title":"Ann. Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.25811","article-title":"Evolution of Alzheimer's disease cerebrospinal fluid biomarkers in early Parkinson's disease","volume":"88","author":"Irwin","year":"2020","journal-title":"Ann. Neurol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"149620","DOI":"10.1016\/j.bbrc.2024.149620","article-title":"Extracellular vesicles contain filamentous alpha-synuclein and facilitate the propagation of Parkinson's pathology","volume":"703","author":"Ishiguro","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B93","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","article-title":"Glial fibrillary acidic protein in the cerebrospinal fluid of alzheimer's disease, dementia with lewy bodies, and frontotemporal lobar degeneration","volume":"136","author":"Ishiki","year":"2016","journal-title":"J. Neurochem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"134576","DOI":"10.1016\/j.neulet.2019.134576","article-title":"Impaired metabolism of kynurenine and its metabolites in CSF of Parkinson's disease","volume":"714","author":"Iwaoka","year":"2020","journal-title":"Neurosci. Lett."},{"key":"B95","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000113679","article-title":"Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia","volume":"5","author":"Jellinger K","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s007020200027","article-title":"Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease","volume":"109","author":"Jellinger","year":"2002","journal-title":"J. Neural Transm."},{"key":"B97","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","article-title":"Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism","volume":"91","author":"Jiang","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"B98","doi-asserted-by":"crossref","first-page":"738530","DOI":"10.3389\/fneur.2021.738530","article-title":"Profiling of differentially expressed microRNAs in Saliva of Parkinson's disease patients","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Neurol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"135259","DOI":"10.3389\/fneur.2021.738530","article-title":"Association of inflammatory factors and aging in Parkinson's disease","volume":"736","author":"Jin","year":"2020","journal-title":"Neurosci. Lett"},{"key":"B100","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-130995","article-title":"Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with lewy bodies, Parkinson's Disease, and Alzheimer's Disease","volume":"38","author":"Kaerst","year":"2013","journal-title":"J Alzheimer Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's progression markers initiative study","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jamaneurol.2013.3861","article-title":"Association of cerebrospinal fluid beta-amyloid 1\u201342, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","article-title":"Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson's disease","volume":"34","author":"Kang","year":"2019","journal-title":"Mov. Disord."},{"key":"B104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cellimm.2018.02.011","article-title":"Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-alpha levels in CSF and serum in relation to the clinical diversity of Parkinson's disease","volume":"327","author":"Karpenko","year":"2018","journal-title":"Cell. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/biomedicines11030728","article-title":"Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease","volume":"11","author":"Keighron","year":"2023","journal-title":"Biomedicines"},{"key":"B106","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders: toward clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/agm2.12192","article-title":"Salivary alpha-synuclein as a potential fluid biomarker in Parkinson's disease: a systematic review and meta-analysis","volume":"5","author":"Kharel","year":"2022","journal-title":"Aging Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.3390\/ijms25105307","article-title":"Potential exosome biomarkers for Parkinson's disease diagnosis: a systematic review and meta-analysis","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jocn.2018.10.079","article-title":"Peripheral blood inflammatory markers in early Parkinson's disease","volume":"58","author":"Kim","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/mds.29766","article-title":"Detecting misfolded a-synuclein in blood years before the diagnosis of Parkinson's disease","volume":"39","author":"Kluge","year":"2024","journal-title":"Mov. Disord."},{"key":"B111","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol Neurodegener"},{"key":"B112","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clineuro.2018.01.022","article-title":"Increased serum levels of TNF-alpha and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity","volume":"166","author":"Kouchaki","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/mds.28122","article-title":"Timing is everything: the T-cell response to alpha-synuclein is maximal in early Parkinson's","volume":"35","author":"Kouli","year":"2020","journal-title":"Mov. Disord."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/jnr.21352","article-title":"Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1","volume":"85","author":"Kurata","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"jcs222406","DOI":"10.1242\/jcs.222406","article-title":"New insights into extracellular vesicle biogenesis and function","volume":"132","author":"Latifkar","year":"2019","journal-title":"J. Cell Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11065-015-9307-8","article-title":"Do CSF biomarkers predict progression to cognitive impairment in Parkinson's disease patients? A systematic review","volume":"25","author":"Leaver","year":"2015","journal-title":"Neuropsychol. Rev."},{"key":"B117","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","article-title":"Epidemiology of Parkinson's disease","volume":"34","author":"Lee","year":"2016","journal-title":"Neurol. Clin."},{"key":"B118","doi-asserted-by":"crossref","first-page":"834580","DOI":"10.3389\/fneur.2022.834580","article-title":"CSF and serum levels of inflammatory markers in PD: Sparse correlation, sex differences and association with neurodegenerative biomarkers","volume":"13","author":"Lerche","year":"2022","journal-title":"Front. Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"776873","DOI":"10.3389\/fnagi.2021.776873","article-title":"Editorial: biomarkers and pathogenesis of alpha Synuclein in Parkinson's disease","volume":"13","author":"Li","year":"2021","journal-title":"Front. Aging Neurosci"},{"key":"B120","first-page":"10470","article-title":"Levels of oligomeric alpha-synuclein in red blood cells are elevated in patients with Parkinson's disease and affected by brain alpha-synuclein expression","volume":"12","author":"Li","year":"2019","journal-title":"Int. J. Clin. Exp. Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"623977","DOI":"10.3389\/fnagi.2021.623977","article-title":"Alterations of erythrocytic phosphorylated alpha-synuclein in different subtypes and stages of Parkinson's disease","volume":"13","author":"Li","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-023-00628-4","article-title":"Candidate biomarkers of EV- microRNA in detecting REM sleep behavior disorder and Parkinson's disease","volume":"10","author":"Li","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"B123","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12974-022-02481-3","article-title":"Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study","volume":"19","author":"Li","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"B124","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fnins.2019.00255","article-title":"Tremor-dominant in Parkinson disease: the relevance to iron metabolism and inflammation","volume":"13","author":"Lian","year":"2019","journal-title":"Front. Neurosci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","article-title":"Reactive astrocytes: production, function, and therapeutic potential","volume":"46","author":"Liddelow","year":"2017","journal-title":"Immunity"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: a biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"","journal-title":"Neurology"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/jcm8101601","article-title":"Plasma pS129-\u03b1-Synuclein is a surrogate biofluid marker of motor severity and progression in Parkinson's disease","volume":"8","author":"Lin","year":"","journal-title":"J. Clin. Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma a-synuclein predicts cognitive decline in Parkinson's disease","volume":"88","author":"Lin","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B129","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12916-023-03120-1","article-title":"Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study","volume":"21","author":"Lin","year":"2023","journal-title":"BMC Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1495769","DOI":"10.3389\/fnagi.2025.1495769","article-title":"Early diagnosis of Parkinson's disease: biomarker study","volume":"17","author":"Lin","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41467-020-15626-w","article-title":"Alpha Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease","volume":"11","author":"Lindestam Arlehamn","year":"2020","journal-title":"Nat. Commun."},{"key":"B132","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","article-title":"Cerebrospinal fluid inflammatory markers in Parkinson's disease\u2013associations with depression, fatigue, and cognitive impairment","volume":"33","author":"Lindqvist","year":"2013","journal-title":"Brain. Behav. Immun."},{"key":"B133","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12974-023-02843-5","article-title":"Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia among de novo Parkinson's disease patients","volume":"20","author":"Liu","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"B134","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","article-title":"Biomarkers for Parkinson's disease: recent advancement","volume":"33","author":"Lotankar","year":"2017","journal-title":"Neurosci. Bull."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2024.08.006","article-title":"Different neurotoxicity and seeding activity between \u03b1-synuclein oligomers formed in plasma of patients with Parkinson's disease and multiple system atrophy","volume":"557","author":"Luo","year":"2024","journal-title":"Neuroscience"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10571-024-01523-z","article-title":"Differences in blood and cerebrospinal fluid between Parkinson's disease and related disorders","volume":"45","author":"Ma","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3233\/JPD-212535","article-title":"Serum neurofilament dynamics predicts cognitive progression in de novo Parkinson's disease","volume":"11","author":"Ma","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1474-4422(24)00395-8","article-title":"Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study","volume":"23","author":"Ma","year":"2024","journal-title":"Lancet Neurol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1038\/s41598-020-65503-1","article-title":"Increased alpha-synuclein tear fluid levels in patients with Parkinson's disease","volume":"10","author":"Maass","year":"2020","journal-title":"Sci. Rep."},{"key":"B140","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2017.01.016","article-title":"Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics","volume":"37","author":"Magdalinou","year":"2017","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"B142","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1567202619666220602125806","article-title":"Biomarkers for Parkinson's disease and neurodegenerative disorders: a role for non-coding RNAs","volume":"19","author":"Maiese","year":"2022","journal-title":"Curr. Neurovasc. Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/mds.26754","article-title":"Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression","volume":"31","author":"Majbour","year":"2016","journal-title":"Mov. Disord."},{"key":"B144","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-020-00192-4","volume":"9","author":"Majbour","year":"2020"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/mds.28611","article-title":"Cerebrospinal \u03b1-synuclein oligomers reflect disease motor severity in DeNoPa longitudinal cohort","volume":"36","author":"Majbour","year":"2021","journal-title":"Mov. Disord."},{"key":"B146","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease","volume":"11","author":"Majbour","year":"2016","journal-title":"Mol. Neurodegener"},{"key":"B147","doi-asserted-by":"publisher","first-page":"148271","DOI":"10.1016\/j.brainres.2023.148271","article-title":"Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease","volume":"1805","author":"Mao","year":"2023","journal-title":"Brain Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jbiotec.2011.01.023","article-title":"Identification of blood microRNAs associated to Parkinson disease","volume":"152","author":"Margis","year":"2011","journal-title":"J. Biotechnol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JPD-191724","article-title":"Senescence and inflammatory markers for predicting clinical progression in Parkinson's disease: the ICICLEPD study","volume":"10","author":"Martin-Ruiz","year":"2020","journal-title":"J. Parkinsons. Dis."},{"key":"B150","doi-asserted-by":"publisher","first-page":"105947","DOI":"10.1016\/j.nbd.2022.105947","article-title":"Oligomeric alpha- synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms","volume":"176","author":"Meloni","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"B151","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10517-020-04723-x","article-title":"Plasma cytokines profile in patients with Parkinson's disease associated with mutations in GBA gene","volume":"168","author":"Miliukhina","year":"2020","journal-title":"Bull. Exp. Biol. Med."},{"key":"B152","doi-asserted-by":"publisher","author":"Miyamoto","year":"2022","DOI":"10.1002\/ana.26510"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","article-title":"Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls","volume":"89","author":"Mollenhauer","year":"2017","journal-title":"Neurology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet. Neurol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid \u03b1-Synuclein in prodromal and early Parkinson's disease","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"key":"B156","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"key":"B157","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/mds.23287","article-title":"CSF A\u03b242 and tau in Parkinson's disease with cognitive impairment","volume":"25","author":"Montine","year":"2010","journal-title":"Mov. Disord."},{"key":"B158","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/bs.irn.2015.05.003","article-title":"Proteomics approach to identify biomarkers in neurodegenerative diseases","volume":"121","author":"Nayak","year":"2015","journal-title":"Int. Rev. Neurobiol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fnins.2020.00438","article-title":"Differential expression of plasma exo- miRNA in neurodegenerative diseases by next- generation sequencing","volume":"14","author":"Nie","year":"2020","journal-title":"Front. Neurosci."},{"key":"B160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.parkreldis.2021.07.028","article-title":"Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD)","volume":"90","author":"Niemman","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"B161","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/ene.14208","article-title":"A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression","volume":"27","author":"Niu","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41592-021-01174-8","article-title":"L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma","volume":"18","author":"Norman","year":"2021","journal-title":"Nat. Methods"},{"key":"B163","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J. Alzheimers. Dis."},{"key":"B164","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2018.11.021","article-title":"Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases","volume":"61","author":"Ohmichi","year":"2019","journal-title":"Parkinsonism. Relat. Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat. Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/mds.25589","article-title":"The glial marker YKL-40 is decreased in synucleinopathies","volume":"28","author":"Olsson","year":"2013","journal-title":"Mov. Disord."},{"key":"B167","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson's from controls","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov Disord"},{"key":"B168","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JPD-160779","article-title":"Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the past decade?","volume":"6","author":"Oueslati","year":"2016","journal-title":"J. Parkinsons. Dis."},{"key":"B169","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","article-title":"Role of post-translational modifications in modulating the structure, function, and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies","volume":"183","author":"Oueslati","year":"2010","journal-title":"Prog. Brain Res."},{"key":"B170","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.parkreldis.2022.05.020","article-title":"Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease","volume":"105","author":"Pagonabarraga","year":"2022","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B171","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/biom10020335","article-title":"The challenge of disease-modifying therapies in Parkinson's disease: role of CSF Biomarkers","volume":"10","author":"Paoletti","year":"2020","journal-title":"Biomolecules"},{"key":"B172","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neulet.2017.11.012","article-title":"Alpha-synuclein dimerization in erythrocytes of patients with genetic and non- genetic forms of Parkinson's disease","volume":"672","author":"Papagiannakis","year":"2018","journal-title":"Neurosci. Lett."},{"key":"B173","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","article-title":"Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease","volume":"7","author":"Park","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","article-title":"Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease","volume":"6","author":"Parnetti","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"B175","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson's disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet. Neurol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"107240","DOI":"10.1016\/j.parkreldis.2024.107240","article-title":"A systematic review of biofluid phosphorylated \u03b1-synuclein in Parkinson's disease","volume":"132","author":"Pedersen","year":"2025","journal-title":"Parkinsonism Relat. Disord."},{"key":"B177","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12974-019-1482-8","article-title":"Plasma VCAM1 levels correlate with disease severity in Parkinson's disease","volume":"16","author":"Perner","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"B178","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/cbic.201300103","article-title":"A label-free, quantitative assay of amyloid fibril growth based on intrinsic fluorescence","volume":"14","author":"Pinotsi","year":"2013","journal-title":"ChemBioChem"},{"key":"B179","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B180","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2022","journal-title":"Brain"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B182","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00702-022-02464-x","article-title":"Serum neurofilament light chain and postural instability\/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study","volume":"129","author":"P\u00f6tter-Nerger","year":"2022","journal-title":"J Neural Transm (Vienna)."},{"key":"B183","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.24962","article-title":"The neuropathology of genetic Parkinson's disease","volume":"27","author":"Poulopoulos","year":"2012","journal-title":"Mov. Disord."},{"key":"B184","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fneur.2019.00384","article-title":"C-reactive protein and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"10","author":"Qiu","year":"2019","journal-title":"Front. Neurol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.bbrc.2016.09.090","article-title":"The role of extracellular vesicles in neurodegenerative diseases","volume":"483","author":"Quek","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B186","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.parkreldis.2019.09.008","article-title":"Neuronal exosomes in saliva of Parkinson's disease patients: a pilot study","volume":"67","author":"Rani","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"B187","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science ."},{"key":"B188","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12916-023-03031-1","article-title":"Fluorescence-tagged salivary small extracellular vesicles as a nanotool in early diagnosis of Parkinson's disease","volume":"21","author":"Rastogi","year":"2023","journal-title":"BMC Med."},{"key":"B189","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson's disease: a systematic review and meta-analysis","volume":"86","author":"Rizzo","year":"2016","journal-title":"Neurology"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1007\/s12035-017-0404-y","article-title":"Reduced activated T lymphocytes (CD4+CD25+) and plasma levels of cytokines in Parkinson's disease","volume":"55","author":"Rocha","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/WNL.0000000000003840","article-title":"Decrease in A\u03b242 predicts dopa-resistant gait progression in early Parkinson disease","volume":"88","author":"Rochester","year":"2017","journal-title":"Neurology"},{"key":"B192","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body- associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01292-6","article-title":"High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease","volume":"9","author":"Russo","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"B194","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ibneur.2023.03.004","article-title":"Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease: a cross-sectional study","volume":"14","author":"Sabaei","year":"2023","journal-title":"IBRO Neurosci. Rep."},{"key":"B195","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","article-title":"Parkinson disease with dementia: comparing patients with and without Alzheimer pathology","volume":"23","author":"Sabbagh","year":"2009","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B196","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s12017-018-8499-5","article-title":"Cerebrospinal fluid C-reactive protein in Parkinson's disease: associations with motor and non-motor symptoms","volume":"20","author":"Sanjari Moghaddam","year":"2018","journal-title":"Neuromolecular. Med."},{"key":"B197","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12883-020-1608-8","article-title":"Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms","volume":"20","author":"Santaella","year":"2020","journal-title":"BMC Neurol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","article-title":"Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies","volume":"12","author":"Schmid","year":"2013","journal-title":"Mol. Cell. Proteomics"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3389\/fneur.2018.01081","article-title":"Immune cell activation in the cerebrospinal fluid of patients with Parkinson's disease","volume":"9","author":"Schroder","year":"2018","journal-title":"Front. Neurol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/mds.28738","article-title":"Systematic assessment of 10 biomarker candidates focusing on \u03b1-synuclein-related disorders","volume":"36","author":"Schulz","year":"2021","journal-title":"Mov. Disord."},{"key":"B201","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41983-020-0159-7","article-title":"Salivary alpha-synuclein (total and oligomeric form): potential biomarkers in Parkinson's disease","volume":"56","author":"Shaheen","year":"2020","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jalz.2016.04.003","article-title":"CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease","volume":"12","author":"Shi","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B203","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuroscience.2019.05.015","article-title":"Central nervous system-derived exosomal alpha-synuclein in serum may be a biomarker in Parkinson's disease","volume":"413","author":"Si","year":"2019","journal-title":"Neuroscience"},{"key":"B205","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Parkinson's progression markers initiative. assessment of heterogeneity among participants in the Parkinson's progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet. Neurol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"B207","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.25824","article-title":"Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies","volume":"88","author":"Singer","year":"2020","journal-title":"Ann. Neurol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"08","DOI":"10.3390\/ijms22052737","article-title":"Different miRNA profiles in plasma derived small and large extracellular vesicles from patients with neurodegenerative diseases","volume":"22","author":"Sproviero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.04.027","article-title":"Amyloid-\u03b2 and \u03b1-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease","author":"Stav","year":"2015","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B210","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","article-title":"Phosphorylated alpha- synuclein in parkinson's disease: correlation depends on disease severity","volume":"3","author":"Stewart","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"B211","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/mds.28639","article-title":"alpha-Synuclein in plasma-derived extracellular vesicles is a potential biomarker of Parkinson's disease","volume":"36","author":"Stuendl","year":"2021","journal-title":"Mov. Disord."},{"key":"B212","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/brain\/awv346","article-title":"Induction of alpha- synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies","volume":"139","author":"Stuendl","year":"2016","journal-title":"Brain"},{"key":"B213","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clineuro.2011.11.002","article-title":"Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients","volume":"114","author":"Su","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B214","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson's disease recognize alpha-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"key":"B215","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1007\/s00415-023-11629-x","article-title":"The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD)","volume":"270","author":"Swallow","year":"2023","journal-title":"J. Neurol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1560809","DOI":"10.1080\/20013078.2018.1560809","article-title":"Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: yield, purity and functional potential","volume":"8","author":"Takov","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"B217","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","article-title":"Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia","volume":"9","author":"Tang","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"B218","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-019-0155-y","article-title":"Erythrocytic alpha-synuclein as a potential biomarker for Parkinson's disease","volume":"8","author":"Tian","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson's disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"B220","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40478-018-0624-z","article-title":"The relevance of cerebrospinal fluid \u03b1-synuclein levels to sporadic and familial Alzheimer's disease","volume":"6","author":"Twohig","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"B221","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jocn.2020.04.058","article-title":"Plasma cytokine profile in synucleinophaties with dementia","volume":"78","author":"Usenko","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"B222","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fncel.2014.00156","article-title":"Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and multiple system atrophy","volume":"8","author":"Vallelunga","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"B223","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JAD-160322","article-title":"Cerebrospinal fluid alzheimer's disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort","volume":"54","author":"van Steenoven","year":"2016","journal-title":"J. Alzheimers. Dis."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/mds.111","article-title":"Alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies","volume":"33","author":"van Steenoven","year":"2018","journal-title":"Mov Disord"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3233\/JPD-201988","article-title":"Serum uric acid levels and non-motor symptoms in Parkinson's disease","volume":"10","author":"van Wamelen","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"B226","doi-asserted-by":"publisher","first-page":"e12128","DOI":"10.1002\/jev2.12128","article-title":"Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin","volume":"10","author":"Veerman","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"B227","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00702-018-1857-5","article-title":"Interleukin 6 and complement serum level study in Parkinson's disease","volume":"125","author":"Vesely","year":"2018","journal-title":"J. Neural. Transm."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00702-019-02043-7","article-title":"The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson's disease: preliminary observations","volume":"126","author":"Vesely","year":"2019","journal-title":"J. Neural. Transm."},{"key":"B229","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.nbd.2014.05.030","article-title":"Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b","volume":"69","author":"Villar-Men\u00e9ndez","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"B230","doi-asserted-by":"publisher","first-page":"e0151156","DOI":"10.1371\/journal.pone.0151156","article-title":"Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease","volume":"11","author":"Vivacqua","year":"2016","journal-title":"PLoS ONE"},{"key":"B231","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.parkreldis.2019.02.014","article-title":"Salivary alpha- synuclein in the diagnosis of Parkinson's disease and progressive supranuclear palsy","volume":"63","author":"Vivacqua","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"B232","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jns.2014.05.052","article-title":"Tau protein, beta-amyloid1\u201342 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia","volume":"343","author":"Vranov\u00e1","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"B233","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nbd.2018.04.015","article-title":"Plasma alpha-synuclein and cognitive impairment in the parkinson's associated risk syndrome: a pilot study","volume":"116","author":"Wang","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"B234","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40478-017-0492-y","article-title":"Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers","volume":"5","author":"Wang","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2015.05.030","article-title":"Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease","author":"Wang","year":"2015","journal-title":"Neurosci. Lett."},{"key":"B236","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1007\/s10072-022-06014-x","article-title":"Real-time quaking-induced conversion assay is accurate for Lewy body diseases: a meta-analysis","volume":"43","author":"Wang","year":"2022","journal-title":"Neurol. Sci."},{"key":"B237","doi-asserted-by":"publisher","first-page":"121r","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated alpha- synuclein in Parkinson's disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B238","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40478-024-01873-1","article-title":"A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson's disease","volume":"12","author":"Wang","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"B239","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"B240","doi-asserted-by":"publisher","first-page":"e0135458","DOI":"10.1371\/journal.pone.0135458","article-title":"The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies","volume":"10","author":"Wennstrom","year":"2015","journal-title":"PLoS ONE"},{"key":"B241","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3389\/fneur.2018.00946","article-title":"The peripheral inflammatory response to alpha-synuclein and endotoxin in Parkinson's disease","volume":"9","author":"White","year":"2018","journal-title":"Front. Neurol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejn.13056","article-title":"Oligomeric \u03b1-synuclein and \u03b2-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases","volume":"43","author":"Williams","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/mds.29497","article-title":"Extracellular vesicles for the diagnosis of parkinson's disease: systematic review and meta-analysis","volume":"38","author":"Xylaki","year":"2023","journal-title":"Mov. Disord."},{"key":"B244","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","article-title":"Neuronally derived extracellular vesicle alpha-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"e18513","DOI":"10.1371\/journal.pone.0018513","article-title":"alpha-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients","volume":"6","author":"Yanamandra","year":"2011","journal-title":"PLoS ONE"},{"key":"B246","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3389\/fneur.2018.01123","article-title":"Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson's disease","volume":"9","author":"Yilmaz","year":"2018","journal-title":"Front. Neurol."},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32480-0","article-title":"Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplex single molecule counting","author":"Youssef","year":"2023","journal-title":"Sci. Rep."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3233\/JPD-212694","article-title":"Comparison of different platform immunoassays for the measurement of plasma alpha-synuclein in Parkinson's disease patients","volume":"11","author":"Youssef","year":"2021","journal-title":"J. Parkinsons. Dis."},{"key":"B249","doi-asserted-by":"publisher","first-page":"104428","DOI":"10.1016\/j.xpro.2026.104428","article-title":"Protocol for large-scale, high-yield, high-purity extracellular vesicle purification from human plasma","volume":"7","author":"Zanganeh","year":"2026","journal-title":"STAR Protoc."},{"key":"B250","doi-asserted-by":"publisher","first-page":"104974","DOI":"10.1016\/j.neuint.2021.104974","article-title":"Potential of extracellular vesicles in the Parkinson's disease-pathological mediators and biomarkers","volume":"144","author":"Zhao","year":"2021","journal-title":"Neurochem. Int."},{"key":"B251","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fnagi.2018.00438","article-title":"Increased DJ-1 and alpha-synuclein in plasma neural-derived exosomes as potential markers for Parkinson's disease","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"B252","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neuroscience.2021.06.033","article-title":"Investigation of alpha-synuclein species in plasma exosomes and the oligomeric and phosphorylated alpha-synuclein as potential peripheral biomarker of Parkinson's disease","volume":"469","author":"Zheng","year":"2021","journal-title":"Neuroscience"},{"key":"B253","doi-asserted-by":"publisher","first-page":"567386","DOI":"10.1155\/2015\/567386","article-title":"The diagnostic and differential diagnosis utility of cerebrospinal fluid alpha -synuclein levels in Parkinson's disease: a meta-analysis","volume":"2015","author":"Zhou","year":"2015","journal-title":"Parkinson Dis."},{"key":"B254","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/JPD-223277","article-title":"Blood and cerebrospinal fluid biomarkers of inflammation in Parkinson's disease","volume":"12","author":"Zimmerman","year":"2022","journal-title":"J. Parkinson Dis."},{"key":"B255","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","article-title":"Plasma and serum alpha-synuclein as a biomarker in parkinson's disease: a meta-analysis","volume":"99","author":"Zubelzu","year":"2022","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1835751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:33:18Z","timestamp":1783920798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1835751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":255,"alternative-id":["10.3389\/fnagi.2026.1835751"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1835751","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"1835751"}}